Eduovisual
Respiratory
Noninvasive ventilation: BiPAP indications and monitoring
— The pressure difference (IPAP − EPAP) is the driving pressure that determines ventilation (CO₂ clearance)
— EPAP alone (≈ CPAP) determines oxygenation by recruitment and FRC restoration
— Classic Step 3 triggers: COPD exacerbation with pH 7.25–7.35 and PaCO₂ >45, acute cardiogenic pulmonary edema, immunocompromised hypoxemia (post-transplant, hematologic malignancy), postextubation prophylaxis in high-risk patients, neuromuscular/chest-wall disease with hypoventilation, and obesity hypoventilation syndrome
— Reduces work of breathing → lowers oxygen consumption of diaphragm
— Improves V/Q matching and reduces preload/afterload (especially in CHF)
— Avoids intubation-associated complications: VAP, sedation, delirium, ICU myopathy
— Cardiac or respiratory arrest, agonal breathing
— Inability to protect airway: obtunded, GCS <10, copious secretions, active vomiting, upper GI bleed
— Facial trauma/surgery/burns preventing mask seal
— Hemodynamic instability with shock, life-threatening arrhythmia
— Recent esophageal anastomosis (gastric insufflation risk)
Board pearl: BiPAP's strongest mortality and intubation-rate evidence is in COPD exacerbation and acute cardiogenic pulmonary edema — these are the two scenarios where withholding NIV is a wrong answer on the exam if no contraindications exist.
— Smoker or known COPD with increased dyspnea, sputum volume, sputum purulence (Anthonisen criteria)
— Pursed-lip breathing, tripoding, accessory muscle use
— ABG: respiratory acidosis pH 7.25–7.35, PaCO₂ acutely elevated above chronic baseline, bicarbonate compensated upward chronically
— Trigger history: viral URI, pneumonia, nonadherence to inhalers, β-blocker initiation, smoke exposure
— Sudden orthopnea, paroxysmal nocturnal dyspnea, pink frothy sputum, hypertensive crisis ("SCAPE" – sympathetic crashing acute pulmonary edema)
— Bilateral crackles, S3, elevated JVP, BNP markedly elevated
— Often hypertensive on arrival; BiPAP reduces preload and afterload, improving LV stroke volume
— BMI >30, daytime somnolence, witnessed apneas, morning headache, polycythemia, elevated HCO₃ at baseline
— Presents with chronic hypercapnia acutely worsened by sedatives, anesthesia, or infection
— ALS, myasthenic crisis, Guillain-Barré (with caveat below), muscular dystrophy
— Orthopnea, weak cough, dysphagia, FVC <50% predicted or NIF less negative than −30 cmH₂O
— Key distinction: In Guillain-Barré and myasthenic crisis, NIV is controversial — most board answers favor early intubation rather than BiPAP because of rapidly progressive bulbar weakness and aspiration risk; do not anchor on NIV here
— Thoracic, abdominal, or bariatric surgery patients with atelectasis-driven hypoxemia
— Prophylactic NIV after extubation in high-risk patients (COPD, CHF, obesity) reduces reintubation
Step 3 management: Always document the trigger of decompensation (infection, ischemia, PE, nonadherence) — treating the underlying cause is as important as the NIV order itself, and CCS will penalize a "BiPAP only" approach without parallel etiologic workup and therapy.
— Respiratory rate >24 with accessory muscle use, paradoxical abdominal motion, suprasternal retractions = impending fatigue
— Mental status: must be awake and cooperative enough to protect airway and trigger the ventilator — drowsiness from hypercapnia may improve with NIV, but coma is a contraindication
— Cough strength and secretion burden: copious, thick secretions predict NIV failure
— Facial anatomy: beard, edentulousness, nasogastric tube, craniofacial abnormalities affect mask seal
— BP, HR, perfusion, lactate — shock is a contraindication because positive intrathoracic pressure decreases venous return and can precipitate collapse
— In cardiogenic edema, BiPAP often improves hemodynamics by reducing LV afterload; in RV failure or massive PE, positive pressure can be catastrophic
— Gag reflex, swallow, vomiting, GI bleed, recent emesis → favor intubation
— Pregnancy and obesity increase aspiration risk; ensure NPO and head of bed ≥30°
— Continuous SpO₂, telemetry, arterial blood gas before starting and at 1–2 hours after
— Document baseline mental status (use Kelly-Matthay score or GCS) so improvement or deterioration is measurable
— pH <7.25 after 1–2 hours of optimal NIV
— Persistent RR >35
— Worsening encephalopathy
— APACHE II >29
— Failure of PaCO₂ to fall or pH to rise within 1–2 hours
CCS pearl: On the CCS case, sequence: place patient on continuous pulse oximetry, telemetry, ABG, then order NIV/BiPAP, then reassess in 1 hour with repeat ABG and exam. Skipping the reassessment order is a classic point loss; the simulated clock advances and the patient deteriorates silently if you do not recheck the gas.
— Distinguishes type I (hypoxemic, PaO₂ <60, normal/low PaCO₂) from type II (hypercapnic, PaCO₂ >45) failure
— Identifies acute, chronic, or acute-on-chronic acidosis by comparing pH to bicarbonate
— Acute respiratory acidosis: HCO₃ rises ~1 mEq/L per 10 mmHg PaCO₂
— Chronic: HCO₃ rises ~3.5 mEq/L per 10 mmHg PaCO₂
— Venous blood gas can screen pH and HCO₃ but arterial is required to trend PaCO₂ under NIV
— Hyperinflation, flattened diaphragms → COPD
— Bilateral perihilar "bat-wing" infiltrates, Kerley B lines, effusions, cardiomegaly → cardiogenic edema
— Lobar consolidation → pneumonia (relative caution with NIV; trial is acceptable if no shock)
— Look for pneumothorax — a contraindication to positive pressure without a chest tube
— Rule out STEMI/NSTEMI as the trigger of pulmonary edema
— Right heart strain (S1Q3T3, RBBB) raises concern for PE — NIV may be unsafe if RV is failing
— BNP/NT-proBNP to support cardiogenic etiology
— Troponin — often mildly elevated from demand; marked rise suggests ACS
— CBC, BMP, lactate — acidosis sources, renal function, infection
— Procalcitonin — adjunct for bacterial infection
— D-dimer if PE suspected (with caveats in pregnancy/age adjustment)
— B-lines bilaterally → pulmonary edema
— Reduced LV function, plethoric IVC → cardiogenic
— RV dilation → PE/cor pulmonale
— Lung sliding absent → pneumothorax (must address before NIV)
Board pearl: A patient with acute respiratory acidosis and pH 7.25–7.35 from COPD is the textbook BiPAP win — choose NIV over intubation, recheck ABG at 1–2 hours, and only escalate if pH worsens or fails to improve.
— ↑ pH by ≥0.05 and ↓ PaCO₂ → continue NIV, titrate settings
— Static or worsening pH after settings optimized → intubate
— A falling RR and improving mental status corroborate gas improvement
— Spirometry confirms obstructive pattern (FEV1/FVC <0.7) in COPD candidates for chronic NIV
— Negative inspiratory force (NIF) and forced vital capacity (FVC) in neuromuscular disease
— NIF less negative than −20 to −30 cmH₂O or FVC <15–20 mL/kg → impending failure; in GBS/MG, favor intubation
— Required for chronic BiPAP/CPAP titration in OSA, obesity hypoventilation, central apnea
— Distinguishes obstructive (treat with CPAP first; BiPAP if intolerant or hypoventilation) from central apnea (consider BiPAP-ST or adaptive servoventilation — avoid ASV in HFrEF with LVEF ≤45%, a black-box safety signal)
— LV systolic/diastolic function, valvular disease, RV size and function
— Guides chronic management after acute cardiogenic edema episode
— When PE, mass, or atypical pneumonia suspected
— Do not delay NIV for CT in unstable patient — stabilize on NIV first if appropriate
— Useful for trend monitoring on NIV, especially when arterial access is limited
— Recognize that EtCO₂ underestimates PaCO₂ in V/Q mismatch
Step 3 management: For a stable hypercapnic patient newly placed on chronic home BiPAP, order outpatient sleep medicine referral, overnight oximetry, and a follow-up ABG in 4–6 weeks to confirm CO₂ normalization. Adherence data download (≥4 hours/night on ≥70% of nights over 30 days) is the CMS standard to continue device coverage.
— Hypercapnic + reversible trigger (COPD exacerbation, OHS decompensation, opioid wear-off) → strong NIV indication
— Hypoxemic from cardiogenic edema → strong NIV indication
— Hypoxemic from ARDS/pneumonia/sepsis → NIV is controversial; high-flow nasal cannula (HFNC) often preferred; if NIV used, set strict 1–2 hour failure threshold
— De novo hypoxemic respiratory failure in immunocompromised → trial NIV or HFNC; low threshold to intubate
— Oronasal (full face) mask is first-line for acute failure (mouth breathing common)
— Mode: spontaneous (S) if reliable respiratory drive; spontaneous/timed (S/T) with backup rate for neuromuscular, central hypoventilation, or sedation-related hypoventilation
— AVAPS (average volume-assured pressure support) for chronic OHS to guarantee tidal volume
— IPAP 8–10 cmH₂O, EPAP 4–5 cmH₂O, FiO₂ titrated to SpO₂ 88–92% in COPD (avoid hyperoxia → worsened hypercapnia from Haldane effect and V/Q changes), 92–96% in cardiogenic edema
— Titrate IPAP up by 2 cmH₂O every 5–10 min to target RR <25, tidal volume 6–8 mL/kg IBW, improved pH
— Typical effective range: IPAP 12–20, EPAP 5–8
— COPD: bronchodilators, steroids, antibiotics
— CHF: nitrates, diuretics, BP control
— Treat infection, ischemia, PE
Board pearl: Do not withhold oxygen for fear of CO₂ retention — target SpO₂ 88–92% in COPD, not zero oxygen. Hypoxia kills faster than hypercapnia.
— Short-acting bronchodilators: albuterol 2.5 mg + ipratropium 0.5 mg nebulized q4h, deliverable through the NIV circuit via in-line nebulizer (do not remove mask)
— Systemic corticosteroids: prednisone 40 mg PO daily × 5 days (or methylprednisolone 40–60 mg IV if NPO); equivalent outcomes
— Antibiotics if Anthonisen criteria (↑dyspnea + ↑sputum volume + ↑purulence) or mechanical ventilation: azithromycin or doxycycline; cover Pseudomonas with piperacillin-tazobactam/cefepime if risk factors
— Avoid theophylline routinely
— IV nitroglycerin 10–20 mcg/min, titrated rapidly in SCAPE (hypertensive) — afterload reduction is the priority
— Loop diuretic (furosemide IV) once perfusion confirmed
— Treat ACS if present (aspirin, heparin, cath lab activation)
— Avoid morphine — associated with increased intubation and mortality
— Continuous albuterol, ipratropium, IV/PO steroids, IV magnesium 2 g
— NIV evidence weaker; reserve for severe cases without contraindications, with early intubation if no response
— Most patients tolerate NIV without sedation
— Low-dose dexmedetomidine (0.2–0.7 mcg/kg/h) is the preferred agent if anxiety/agitation impairs tolerance — preserves respiratory drive
— Avoid benzodiazepines and opioids routinely; they blunt drive and increase failure
Step 3 management: A COPD patient on BiPAP who becomes agitated and tries to remove the mask — do not order lorazepam. Order low-dose dexmedetomidine, reassure, reposition mask, and check for skin breakdown or claustrophobia before assuming NIV failure.
— Patient semi-upright (≥30°), explain procedure, hold mask gently to face first before strapping
— Choose oronasal mask with correct sizing template; avoid overtight straps (two-finger rule under strap)
— Connect humidified circuit; heated humidification improves comfort and secretion clearance
— Start IPAP 8–10 / EPAP 4–5, FiO₂ 0.4, backup rate 12 if S/T mode
— Confirm chest rise, exhaled tidal volume 6–8 mL/kg IBW, leak <30 L/min
— Order ABG at 1 hour, continuous pulse ox, telemetry, end-tidal CO₂ if available
— RR <25, accessory muscle use resolving
— SpO₂ 88–92% (COPD) or 92–96% (cardiogenic/de novo hypoxemic)
— Improving pH and falling PaCO₂ at 1–2 hours
— Increase IPAP to reduce PaCO₂ (improves ventilation); increase EPAP/FiO₂ to improve oxygenation
— Maximum practical IPAP ≈ 20–25 cmH₂O; above this, gastric insufflation and leak dominate
— Ineffective triggering (intrinsic PEEP in COPD) → increase EPAP to counterbalance auto-PEEP
— Auto-triggering from leak → reseat mask, reduce trigger sensitivity
— Double triggering → may need longer inspiratory time or rise time adjustment
— Persistent dyssynchrony despite optimization → consider intubation
— Preferred in de novo hypoxemic failure (e.g., pneumonia, post-extubation, mild ARDS, immunocompromised)
— Delivers 30–60 L/min heated humidified O₂, ~3–5 cmH₂O PEEP effect, improves comfort
— Not a substitute for NIV in hypercapnic failure
CCS pearl: When you order BiPAP on the simulated case, also order: ABG in 1 hour, continuous pulse oximetry, telemetry, head of bed elevation, in-line nebulizers, DVT prophylaxis, and disease-specific therapy. The grader rewards the parallel bundle, not just the NIV order.
— Higher prevalence of COPD, CHF, OSA, and OHS — frequent BiPAP candidates
— Frailty and cognitive impairment reduce tolerance; delirium worsens with mask claustrophobia
— Skin is thin — pressure ulcers on nasal bridge develop within hours; use prophylactic hydrocolloid dressings and rotate masks (oronasal alternating with total face) every 4–6 hours
— Aspiration risk is higher: confirm swallowing/secretion management before and during NIV
— Goals of care discussion is essential — NIV is sometimes deployed as a "ceiling of therapy" in patients with DNI orders; document clearly
— BiPAP itself is not nephrotoxic, but positive intrathoracic pressure can reduce cardiac output and renal perfusion in volume-depleted patients
— Monitor urine output, BUN/creatinine daily
— Adjust co-administered drugs (e.g., renal-dose enoxaparin 30 mg daily if CrCl <30, switch to unfractionated heparin for severe AKI, avoid NSAIDs)
— In ESRD, fluid shifts during dialysis interact with NIV — coordinate diuresis/UF with respiratory plan
— Hepatic encephalopathy lowers airway protection — if grade III–IV, intubate rather than NIV
— Hepatopulmonary syndrome causes refractory hypoxemia poorly responsive to PEEP
— Adjust sedation: avoid benzodiazepines; dexmedetomidine preferred but reduce dose
— Reconcile opioids, gabapentinoids, benzodiazepines, sedating antihistamines — these contribute to hypercapnia and can be the reversible cause of presentation
— Consider naloxone if opioid-related hypoventilation suspected before committing to NIV
Board pearl: In an elderly DNI/DNR patient with hypercapnic COPD exacerbation, BiPAP is not futile — it can be definitive therapy and is consistent with comfort-focused goals when it relieves dyspnea; clarify ceiling-of-care orders explicitly in the chart.
— Physiologic baseline: chronic respiratory alkalosis (PaCO₂ ≈ 30); a "normal" PaCO₂ of 40 in a pregnant patient signals impending respiratory failure
— NIV indications same as nonpregnant but aspiration risk is higher (decreased LES tone, delayed gastric emptying); aggressive head-of-bed elevation, antacid
— Asthma in pregnancy — treat aggressively; NIV can bridge severe exacerbations
— Peripartum cardiomyopathy with pulmonary edema — NIV plus diuresis, nitrates (caution with hypotension), coordinate with OB for delivery planning
— Avoid hypoxemia at all costs — fetal oxygenation depends on maternal SpO₂ >95%
— BiPAP used in bronchiolitis, status asthmaticus, OSA, neuromuscular disease
— Smaller masks, pediatric circuits; sedation sometimes needed for tolerance
— Lower pressure ranges (IPAP 8–12, EPAP 4–6)
— Have intubation readiness; pediatric airways fatigue faster
— Defined: BMI ≥30 + awake PaCO₂ ≥45 + no alternative cause
— Often coexists with OSA (~90%); polysomnography required for chronic titration
— Chronic therapy: CPAP first-line if OSA-predominant, BiPAP-ST or AVAPS if hypoventilation persists despite CPAP or pH/PaCO₂ remains abnormal
— Acute decompensation: oronasal BiPAP, diuresis if volume overloaded, weight management referral
— Weight loss (including bariatric surgery referral if BMI ≥35 with comorbidity) is disease-modifying
— Resume home CPAP/BiPAP immediately postop; positive pressure does not disrupt fresh anastomoses at typical home pressures (data reassuring)
— Document home settings on admission medication reconciliation
Key distinction: OSA → CPAP first. OHS or COPD-OSA overlap with persistent hypercapnia → BiPAP. Confusing these is a classic Step 3 distractor.
— Nasal bridge pressure ulcers — most common; preventable with hydrocolloid dressings, mask rotation, correct sizing
— Claustrophobia, anxiety, agitation — try smaller nasal mask or total-face mask
— Air leaks → dry eyes (conjunctivitis), noise, asynchrony
— Skin maceration from humidity
— Risk rises with IPAP >20 cmH₂O
— Mitigate: keep IPAP as low as effective, head of bed ≥30°, consider NG tube if persistent distension (vented through mask port)
— Aspiration pneumonitis is the most feared acute complication
— ↓ Venous return → hypotension, especially in hypovolemic or RV-failure patients
— In cardiogenic edema, hemodynamics usually improve
— Monitor BP every 5–15 min during initiation
— Pneumothorax, pneumomediastinum — rare at typical pressures; higher risk in bullous emphysema, asthma
— New chest pain, sudden desaturation, unilateral breath sounds → immediate CXR/POCUS, chest tube before continuing positive pressure
— Delayed intubation increases mortality — recognize failure criteria early
— Failure predictors: pH <7.25 at 1 hr, RR persistently >35, GCS decline, hemodynamic deterioration, copious secretions, severe asynchrony
— Insufficient EPAP (<4) or inadequate exhalation port can cause rebreathing
— Worsening hypercapnia despite NIV — check circuit, increase EPAP, ensure adequate IPAP-EPAP gradient
Board pearl: The single biggest patient-safety error with NIV is persisting too long on a failing trial. If at 1–2 hours the pH is unchanged or worse, intubate — do not "give it more time."
— Many centers permit step-down/intermediate care for stable COPD on NIV with experienced staff and continuous monitoring — verify local capability
— Acute cardiogenic edema responsive within 1–2 hours may downgrade to telemetry floor
— pH <7.25 not improving after 1–2 hours optimized
— Persistent RR >35 with accessory muscle use
— Declining mental status (rising PaCO₂ narcosis)
— Hemodynamic instability, new arrhythmia, MI
— Inability to clear secretions, vomiting, aspiration
— Mask intolerance not resolved with troubleshooting
— Cardiac or respiratory arrest
— Pulmonology/critical care at initiation for all acute NIV
— Cardiology for cardiogenic edema with ACS or new HFrEF
— Sleep medicine for chronic BiPAP titration, OSA/OHS workup
— Palliative care when NIV is being deployed as a comfort/ceiling-of-care measure or when DNI status changes the framing
— Neurology for neuromuscular failure (myasthenia, ALS, GBS)
— Patient on NIV is not safely transferred between facilities without transport ventilator capable of delivering bilevel pressures, trained crew, secured airway plan, and ABG-confirmed stability
— Document settings, mask type, FiO₂, last ABG, and code status on transfer paperwork
CCS pearl: When escalating from floor to ICU on a CCS case, move the patient to ICU first, then order intubation if criteria met. Ordering intubation on the floor without location change is a frequent omission that costs points and creates real-world risk.
— Hypercapnic, prior smoking, wheeze, hyperinflation; strongest NIV evidence
— Treat with NIV + bronchodilators + steroids + antibiotics
— Hypoxemic ± mild hypercapnic, orthopnea, JVD, S3, BNP↑, bilateral B-lines
— NIV reduces preload/afterload, intubation rate, and mortality
— Differentiate from ARDS by echo, BNP, history
— Younger, wheeze, prior asthma, normal CXR
— NIV evidence modest; intubate early if no response
— Focal or bilateral infiltrates, fever, sepsis
— NIV often fails; HFNC or early intubation preferred, especially with PaO₂/FiO₂ <200
— Awake proning may help in select patients
— Chronic hypercapnia, daytime somnolence, obesity
— Acute decompensation responds well to NIV; chronic management with home CPAP/BiPAP
— MG, ALS, GBS, muscular dystrophy
— NIV appropriate for chronic ALS/dystrophy; avoid as primary therapy in GBS and myasthenic crisis — intubate when FVC <15–20 mL/kg or NIF >−20 cmH₂O
— Opioid overdose, sedative excess — treat the cause (naloxone, reversal) first; NIV is bridge therapy if drive returns
— Hypoxemia after thoracic/abdominal surgery — NIV/CPAP improves oxygenation and reduces reintubation
Key distinction: Hypercapnic failure with reversible cause → NIV wins. De novo hypoxemic failure (ARDS, pneumonia) → HFNC or early intubation; NIV is a cautious trial at best.
— Acute hypoxemic dyspnea with clear lungs, tachycardia, RV strain on ECG/echo
— Positive pressure ventilation worsens RV afterload — can precipitate cardiac arrest in massive PE
— Treat the PE (anticoagulation ± thrombolysis); use NIV cautiously and only with hemodynamic monitoring
— Sudden pleuritic pain, unilateral absent breath sounds, hyperresonance
— NIV is contraindicated until chest tube placed; positive pressure converts simple to tension pneumothorax
— Positive intrathoracic pressure further reduces preload; avoid NIV and treat cause (pericardiocentesis, decompression)
— Patient hyperventilates to compensate; CO₂ is low, pH is low from metabolic cause
— NIV is not indicated — treat the metabolic problem; intubation with caution because matching minute ventilation under anesthesia is dangerous (avoid intubation if possible)
— NIV cannot bypass fixed obstruction; secure airway with intubation or surgical airway
— Airway not protected; intubate
— Normal ABG except respiratory alkalosis; reassurance and treating underlying cause, not NIV
— SpO₂ misleading; treat with 100% O₂, hyperbaric (CO), antidotes (cyanide) — NIV not the answer
Step 3 management: Before placing BiPAP on a hypoxic, tachypneic patient, explicitly rule out pneumothorax and consider PE. A bedside ultrasound takes 60 seconds and prevents catastrophic NIV misuse.
— LABA/LAMA combination inhaler as baseline maintenance; add ICS if eosinophils ≥300 or frequent exacerbations
— Smoking cessation — counsel at every visit, offer varenicline or combination NRT, set quit date
— Pulmonary rehabilitation referral within 4 weeks (mortality and readmission benefit)
— Vaccines: influenza annually, COVID-19, pneumococcal (PCV20 or PCV15 + PPSV23), Tdap, RSV (≥60), zoster (≥50)
— Assess for long-term home NIV if PaCO₂ ≥52 persistently or ≥2 admissions for hypercapnic failure (improves mortality)
— Long-term oxygen if resting SpO₂ ≤88% or PaO₂ ≤55 (mortality benefit)
— GDMT: ARNI (or ACEi/ARB), evidence-based beta-blocker, MRA, SGLT2 inhibitor
— Diuretic titration with daily weights
— Salt and fluid restriction, BP control
— Cardiac rehab referral
— Home CPAP or BiPAP with adherence monitoring; goal ≥4 hours/night on ≥70% of nights
— Weight loss (lifestyle, pharmacotherapy, bariatric surgery referral if BMI ≥35 with comorbidity)
— Avoid alcohol and sedatives at bedtime
— Driving counseling if excessive daytime sleepiness
— Home NIV initiation when symptomatic hypoventilation, orthopnea, FVC <50%, or nocturnal hypercapnia
— Cough-assist device, secretion management, advance care planning early
Board pearl: A COPD patient with ≥2 hospitalizations for hypercapnic respiratory failure in the past year is a candidate for long-term home NIV — this is a newer USPSTF/ATS-supported intervention with mortality and readmission benefit, increasingly tested on Step 3.
— Continuous SpO₂, telemetry, RR documented hourly
— ABG at baseline, 1 hour, 4 hours, then as clinically indicated
— Mental status checks q1–2h initially
— Skin checks for pressure injury q4h with mask removal
— Daily chest exam, fluid balance, weights
— Criteria: pH normalized, RR <24, PaCO₂ at baseline, FiO₂ ≤0.4, hemodynamics stable, mental status normal
— Trial off NIV for 1–2 hours during the day with monitoring
— Many COPD/OHS patients benefit from nocturnal-only NIV continuation at discharge
— Within 7 days of any respiratory hospitalization (CMS readmission metric)
— Pulmonology or sleep medicine within 4 weeks if home NIV/CPAP initiated
— Cardiology within 7–14 days post-cardiogenic edema admission
— Repeat spirometry, ABG, or polysomnography at 4–6 weeks for chronic NIV titration
— Modern devices transmit nightly adherence, leak, AHI, pressure data via cloud
— Review at each visit; troubleshoot leak, comfort, settings
— CMS requires ≥4 hours on ≥70% of nights over a 30-day period within first 90 days for continued coverage
— Pulmonary rehab (8–12 weeks) for COPD, ILD, post-acute respiratory failure
— Cardiac rehab post-HF
— Smoking cessation, weight management, sleep hygiene, exercise
— Inhaler technique review at every visit
— Action plans for early exacerbation recognition
Step 3 management: Schedule the 7-day post-discharge visit before the patient leaves the hospital, with home health for NIV setup if applicable. This single order reduces 30-day readmission and is a high-yield CCS action.
— BiPAP is not innocuous — discuss benefits, mask discomfort, possible escalation to intubation, and the failure trajectory
— In capable patients, document a verbal consent and the plan if NIV fails
— NIV in DNI/DNR patients: explicitly permitted and often appropriate as a ceiling of therapy; clarify and document that escalation to intubation is not planned, and that NIV may be continued for comfort or withdrawn if not tolerated
— Hypercapnia can impair capacity acutely; decisions made during severe respiratory distress should be revisited once gas exchange improves
— If patient lacks capacity, surrogate decision-maker per state hierarchy; use prior advance directives
— Acceptable for symptom relief in end-stage COPD, ALS, or terminal cancer with reversible decompensation
— Establish clear time-limited trials (e.g., 24–48 hours) with predefined success/failure criteria and family meetings
— Driving safety: patients with OSA/OHS and excessive daytime sleepiness must be counseled about driving risk; some states (e.g., California) require physician reporting of lapses of consciousness — know your state law
— Commercial drivers (CDL) have federal medical certification requirements tied to OSA/CPAP adherence
— Failure to communicate home BiPAP settings, mask type, and adherence data at admission is a major Joint Commission–flagged medication-reconciliation failure
— Resume home CPAP/BiPAP on admission (including in surgical patients) to prevent perioperative respiratory failure
— At discharge, ensure DME (durable medical equipment) is set up before the patient leaves
— Skin checks, fall precautions (cords, masks), aspiration precautions, alarm parameters set, code status revisited every shift
Board pearl: A patient with metastatic cancer and DNR/DNI who develops a COPD exacerbation can — and often should — receive BiPAP. DNI ≠ no NIV. Misinterpreting this is a common ethics-question trap.
CCS pearl: The NIV-aware test-taker orders these together: BiPAP, ABG in 1 hour, telemetry, continuous pulse ox, head of bed elevation, in-line nebulizers, disease-specific therapy, DVT prophylaxis, ICU transfer.
— "65-year-old smoker with 2 days of worsening dyspnea, sputum purulence. RR 28, SpO₂ 86% on 2 L NC, ABG: pH 7.28, PaCO₂ 68, PaO₂ 58, HCO₃ 31. Next step?"
— Answer: Initiate BiPAP (not intubation, not just increase O₂). Distractor: "Increase FiO₂ to 100%" — wrong because of hyperoxia-induced worsening hypercapnia
— "78-year-old with HTN, BP 210/110, severe dyspnea, bilateral crackles, B-lines on POCUS, BNP 2200. Next step?"
— Answer: BiPAP + IV nitroglycerin + IV furosemide. Distractor: "IV morphine" — outdated, associated with worse outcomes
— "Patient on BiPAP for COPD × 2 hours. Repeat ABG: pH 7.21, PaCO₂ 82, mental status declining. Next step?"
— Answer: Endotracheal intubation. Do not "continue current therapy."
— "Metastatic cancer patient, DNI/DNR, COPD exacerbation with pH 7.30. Family asks if anything can be done."
— Answer: BiPAP as ceiling of care — consistent with DNI status
— "Pneumonia with PaO₂/FiO₂ 150, RR 32 on NIV × 2 hours, no improvement."
— Answer: Intubate; NIV often fails in ARDS. HFNC could have been first-line.
— "BMI 48, daytime somnolence, AM headaches, ABG: pH 7.36, PaCO₂ 56, HCO₃ 32. Polysomnography shows AHI 35 with hypoventilation."
— Answer: Initiate BiPAP (or AVAPS), weight loss program, sleep medicine follow-up.
— "Asthma exacerbation on BiPAP develops sudden chest pain and unilateral absent breath sounds." → Stop BiPAP, place chest tube.
— Ascending paralysis, FVC falling to 14 mL/kg, NIF −18. → Intubate, not BiPAP.
Board pearl: When the stem gives you pH, PaCO₂, mental status, and a reversible trigger, the right answer is almost always BiPAP + treat cause + reassess in 1 hour.
BiPAP is the first-line ventilatory support for awake, cooperative patients with acute hypercapnic respiratory failure from COPD exacerbation, cardiogenic pulmonary edema, or obesity hypoventilation — initiated with IPAP 10/EPAP 5 titrated to clinical and ABG targets, reassessed at 1–2 hours, and abandoned for intubation if pH fails to improve or the patient deteriorates.
Board pearl: Master three numbers — pH 7.25, SpO₂ 88–92%, 1-hour ABG recheck — and you will answer almost every NIV question correctly on Step 3.